INmune Bio
INMB
33 hedge funds and large institutions have $11.7M invested in INmune Bio in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 6 closing their positions.
123% more call options, than puts
Call options by funds: $350K | Put options by funds: $157K
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.55% less ownership
Funds ownership: 11.23% → 10.67% (-0.55%)
8% less funds holding
Funds holding: 36 → 33 (-3)
33% less capital invested
Capital invested by funds: $17.4M → $11.7M (-$5.72M)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$239K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$209K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$83.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$34.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$23.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$696K |
| 2 |
Renaissance Technologies
New York
|
-$284K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$139K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$134K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$107K |
INMB Hedge Fund Activity: Q3 2022 in Review
33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2022, worth a combined $11.7M — down 33% from $17.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INMB and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $239K. The largest seller was Morgan Stanley, cutting an estimated $696K.
- 33 institutional investors held INmune Bio (INMB) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $11.7M of INmune Bio stock for Q3 2022, down 33% quarter-over-quarter.
- 4 funds opened new INmune Bio positions in Q3 2022 and 6 closed out, a net change of -2 holders.
- The largest INmune Bio buyer in Q3 2022 was Millennium Management, an estimated $239K added.
- The largest INmune Bio seller in Q3 2022 was Morgan Stanley, an estimated $696K sold.
Based on aggregated 13F filings for Q3 2022.